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Cancer drug resistance (CDR) is a central problem in therapeutic failure. Several mechanisms 
can underlie CDR, including increased expression and activity of efflux ABC transporters and epigenetic 
phenomena. A topic that is not usually addressed is the mechanism underlying the loss of resistance to 
therapy once the challenge to these cells is withdrawn.  
A KCR cell line (doxorubicin-resistant and expressing ABCB1) was used to induce loss of 
resistance by withdrawing doxorubicin in culture medium, assess ABCB1 expression and activity and 
determine a signature of microRNAs expression. The activity of ABCB1 was analysed by fluorescence 
microscopy and flow cytometry through fluorescence (DiOC2) substrate retention assays. Expression 
of 1008 microRNAs was assessed before and after doxorubicin withdrawal. 
After 16 weeks of doxorubicin withdrawal we observed a decrease of ABCB1 activity and 
expression. Moreover, we determined a signature of 23 microRNAs, 13 under-expressed and 10 over-
expressed, as a tool to assess loss of resistance. Through pathway enrichment analysis, “Pathways in 
cancer”, “Proteoglycans in cancer” and “ECM-receptor interaction” were identified as relevant pathways 
in loss of CDR. 
Taken together, the data reported reinforces the assumption that ABCB1 may play a major role 
in the kinetics of CDR and their levels of expression are in the dependence of the circuitry of cell miRNAs. 













































A resistência a quimioterápicos no cancro (CDR) é um problema central que limita a 
quimioterapia. Vários mecanismos podem estar envolvidos na CDR, incluindo maior expressão e 
atividade de transportadores de efluxo ABC e fenómenos epigenéticos. Um tópico que geralmente não 
é abordado é o mecanismo envolvido na perda de resistência à quimioterapia uma vez que o estímulo 
para essas células é retirado. 
Uma linha celular KCR (resistente à doxorrubicina e que sobre expressa ABCB1) foi cultivada 
em meio de cultura sem doxorrubicina para induzir a perda de resistência. Foi avaliada a expressão e 
atividade de ABCB1 e determinada uma assinatura da expressão de microRNAs. A atividade de ABCB1 
foi analisada ao longo do tempo por microscopia de fluorescência e citometria de fluxo através de 
ensaios de retenção de um substrato fluorescente (DiOC2). A expressão de 1008 microRNAs foi 
avaliada antes e após a retirada da doxorrubicina.   
Após 16 semanas sem doxorrubicina, observamos uma diminuição da atividade e da expressão 
de ABCB1. Além disso, determinamos uma assinatura de 23 microRNAs, 13 sub-expressos e 10 sobre-
expressos, que podem ser usados para avaliar a perda de resistência. Através da análise de 
enriquecimento de vias, “Vias no cancro”, “Proteoglicanos no cancro” e “Interação ECM-recetor” foram 
identificados como vias relevantes na perda de CDR. 
Tomados em conjunto, os dados descritos reforçam a suposição de que o ABCB1 pode 
desempenhar um papel importante na cinética da CDR e que os seus níveis de expressão podem estar 
dependentes dos miRNAs. 
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Chapter 1. Introduction 
1.1. Breast cancer 
Breast cancer (BC) is the most frequently diagnosed cancer among women, with 2.1 million 
cases diagnosed worldwide in 2018. It is also the leading cause of cancer-related death in women 
(15%), with 626 679 estimated deaths in 2018. Regarding Portugal, the estimated number of incidence 
cases and deaths are 5579 and 795, respectively (WHO, 12-12-2019). 
Once breast cancer is diagnosed, the evaluation of both staging and molecular expressions 
must be considered to evaluate the prognosis and consequently provide the best therapy to each 
tumour type. According to the American Joint Committee on Cancer (AJCC), the staging system is the 
combination of the Tumour, Node, Metastasis (TNM) classification, with a prognostic stage group, 
which represents a combination of tumour grade, oestrogen receptor (ER), progesterone receptor 
(PR), and HER2 status. Breast cancer staging system is divided into: Stage I, Stage II, Stage III and 
Stage IV, as detailed in Table 1. This Anatomic Stage Group is to be used when biomarker tests are 
not available (Feng et al., 2018). 
 
Table 1. Anatomic stage groups of breast cancer 
Stages  Definition 
Stage 0   Ductal Carcinoma In Situ 
Stage I       IA Primary invasive tumour with a size of ≤ 20 mm No nodal 
involvement 
                IB Nodal micrometastases (>0.2 mm, <2.0 mm) with or without ≤20 
mm primary tumour 
Stage II      IA Movable ipsilateral Level I, II lymph node metastases with ≤20 
mm primary tumour; Or >20 mm, ≤50 mm tumour with no nodal 
involvement 
               IIB Movable ipsilateral Level I, II lymph node metastases with>20 
mm,50 mm tumour; Or >50 mm tumour with no nodal 
involvement 
Stage III   IIIA Movable ipsilateral Level I, II lymph node metastases with>50 
mm tumour; Or any size primary tumour with fixed ipsilateral 
Level I, II or internal lymph node metastases 
 IIIB Primary tumour with chest wall and/or skin invasion 
 IIIC Any size primary tumour with supraclavicular or ipsilateral Level 
III lymph node metastases; Or with ipsilateral Level I, II and 
internal lymph node metastases 
Stage IV  Any case with distant organ metastasis 
Source (Feng et al., 2018) 
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In the United States, it is estimated that there are more than 3.8 million women alive with a 
history of invasive breast cancer of which more than 150,000 BC survivors are living with metastatic 
disease. The number of BC survivors continues to grow in the United States and worldwide. This 
growing number of survivors might result from growth and aging of the population as well as advances 
in early detection and treatment (Miller et al., 2019). 
There are several treatment options for BC, typically, treatment plans are based on type, stage, 
and other factors such as overall health of the patient. In the USA, the most common treatment among 
women with early‐stage BC (stage I or II) is breast‐conserving surgery (BCS) with adjuvant radiation 
therapy (49%), a small number of patients in this stage received chemotherapy (18%) (Figure 1.1).  
Patients with stage III BC, most often undergo mastectomy with adjuvant chemotherapy and 
radiotherapy (45%). Women diagnosed with metastatic disease (stage IV) most often receive radiation 
and/or chemotherapy alone (56%), and 26% receive no treatment (Figure 1). Among patients with 
hormone receptor–positive tumours, 81% receive hormonal therapy, and 71% of those with metastatic 
disease (Miller et al., 2019). 
 
 
Systemic therapy of BC includes the use of cytotoxic, hormonal, and immunotherapeutic 
agents. This therapy for nonmetastatic breast cancer is determined by subtype: patients with hormone 
receptor–positive tumours receive endocrine therapy, and a minority receive chemotherapy as well; 
patients with ERBB2-positive tumours can receive ERBB2-targeted antibody or small-molecule 
inhibitor therapy combined with chemotherapy; and patients with triple-negative tumours receive 
chemotherapy alone (Gomes, Rueff, & Rodrigues, 2012; Nikolaou, Pavlopoulou, Georgakilas, & 
Kyrodimos, 2018; Si, Shen, Zheng, & Fan, 2019).  
 
 Figure 1.1: Female Breast Cancer Treatment Patterns (%) by Stage, 2016. *A small number of these patients received 
chemotherapy. †A small number of these patients received radiation therapy (RT). BCS indicates breast-conserving surgery; 
chemo, chemotherapy (includes targeted therapy and immunotherapy).  
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As we can see, chemotherapy plays an important role in the comprehensive treatment of BC. 
Moreover, multiple studies have demonstrated that adjuvant therapy for early-stage breast cancer 
produces a 23% or higher improvement in disease-free survival and a 15% or higher increase in overall 
survival rates (Gonzalez-Angulo, Morales-Vasquez, & Hortobagyi, 2007). Chemotherapy treatment 
use drugs to stop the growth of cancer cells, either by killing the cells or by arresting cell division and 
can be used in different ways. Knowing how the drug works is important in predicting side effects from 
it and which drugs work well together when more than one drug will be use (Table 2).  
 
Table 2. Mechanisms of action for cancer drugs used to treat Breast Cancer 
Drugs Mechanism of action 
Anthracyclines Pleiotropic effects, including activation of signal transduction 
pathways, generation of reactive oxygen intermediates, stimulation of 
apoptosis, and inhibition of DNA topoisomerase II catalytic activity 
Taxanes High-affinity binding to microtubules with enhanced microtubule 
formation at high drug concentrations and inhibition of mitosis. 
Antimetabolites         Ability to interfere with key enzymatic steps in nucleic acid metabolism. 
Inhibition of dihydrofolate reductase (DHFR) leads to partial depletion 
of reduced folates. Polyglutamates of MTX and dihydrofolate inhibit 
purine and thymidylate biosynthesis. 
Alkylating Agents and 
Platinum agents 
Produce alkylation of DNA through the formation of reactive 
intermediates that attack nucleophilic sites. 
Vinca Alkaloids              Inhibition of polymerization of tubulin and DNA topoisomerase I 
Gemcitabine Inhibits DNA polymerase α, is incorporated into DNA, and terminates 
DNA-chain elongation. 
Tamoxifen Binds to the estrogen receptor (ER) and induces dimerization and DNA 
binding to finally inactivate it. 
Trastuzumab Is a humanized monoclonal antibody that selectively binds with high 
affinity to the extracellular domain of HER-2. It inhibits tumor-cell 
proliferation through antibody-dependent cellular toxicity, inducing 
apoptosis, inhibiting HER-2/neu intracellular, signalling pathways, and 
downregulating expression of HER-2 receptors. It also has synergistic 
action in combination with chemotherapy drugs. 
Source (Gonzalez-Angulo et al., 2007) 
 
Anthracycline-based treatments are preferred, particularly represented by doxorubicin (DOX). 
Doxorubicin is a class I anthracycline drug with aglyconic and sugar moieties, isolated from 
the Streptomyces peucetius species. Despite its inherent toxicity that affects the heart, brain, liver and 
kidneys, DOX is still one of the most used drugs in cancer treatment (Meredith & Dass, 2016; Tacar, 




There are some proposed mechanisms by which DOX acts in the cancer cell: (i) by binding to 
multiple molecular targets such as topoisomerase enzyme II (TOP2), which regulates DNA 
superhelical state, relaxing accumulated positive supercoils, as well as unlinking intertwined DNA 
strands. During replication, TOP2 induces double-strand breaks in DNA, and DOX then acts by 
stabilizing TOP2-DNA covalent cleavage intermediates, which will inhibit cellular growth and trigger 
the apoptosis pathway; (ii)  intercalation into DNA inhibiting both DNA and RNA polymerases, ceasing 
DNA replication as well as transcription;  (iii) production of free radicals that leads to membrane, DNA 
and protein damage (Figure 1.2). Briefly, DOX is oxidized to semiquinone, an unstable metabolite, 
which can be converted back to DOX in a process that releases reactive oxygen species (ROS). These 
ROS will lead to lipid peroxidation and DNA and mitochondrial damage that triggers an apoptotic 
cascade activated by cytochrome c release from the mitochondria. (Houshmand, Dehghan Manshadi, 
Faraji, Mobaraki, & Zare, 2016; Meredith & Dass, 2016; Tacar et al., 2013) 
 
 
Figure 1.2: Doxorubicin effects in cell death. Doxorubicin blocks DNA synthesis by suppression of TOP2 and 
inhibiting both DNA and RNA polymerases via intercalation into DNA. Furthermore, leads to ROS formation, 
causing lipid peroxidation and DNA and mitochondrial damage. DOX: doxorubicin, ROS: Reactive Oxygen 






1.2. Chemotherapeutic resistance  
In many cases, chemotherapy attains a good response, by reducing tumour volume, improving 
symptoms, and decreasing serological tumour markers. However, after a variable period, recurrence 
may occur. This recurrence can be local or distant, but in general, distance recurrences are dominant. 
At this point, resistance to therapy is not only common, it is expected and limits the effectiveness of 
chemotherapies leading to treatment failure (Figure 1.3) (Gonzalez-Angulo et al., 2007).  
 
Figure 1.3 Drug resistance in chemotherapy treatment. Source: Chemoth.com, 20-03-2020.  
Drug resistance can be divided into intrinsic and acquired drug resistance. Intrinsic or primary 
drug resistance occurs in tumour cells which show some inherent characteristics of resistance to 
anticancer drugs since the beginning of therapy (Gomes, Rueff, & Rodrigues, 2016; Rueff & 
Rodrigues, 2016). Acquired or secondary drug resistance occurs when tumour cells develop drug 
resistance during treatment that were initially sensitive to drug treatment (Gomes et al., 2012; Marin, 
Briz, Rodríguez-Macias, Díez-Martín, & Macias, 2016).  
With the objective of overcoming resistance, the use of combinations of more than one drug 
has been adopted. However, during chemotherapy cycles, tumour cells are prone to develop cross-
resistance to a variety of chemotherapeutic drugs with different structure and function, even to drugs 
to which they have not been exposed previously, resulting in so-called multidrug resistance (MDR) 
phenotype (Li & Lai, 2017; Marin et al., 2016). Consequently, the anti-cancer effects of 
chemotherapeutic drugs decrease and all initially responsive tumours that are originally sensitive to a 
single anti-cancer drug, later, become resistant to multiple anti-cancer drugs (Dei, Braconi, Romanelli, 
& Teodori, 2019). This phenotype was first described in 1970 by Biedler & Riehm (1970) in Chinese 
hamster lung cells. They refer to cross resistance of actinomycin-D resistant cells with mithramycin, 
vinblastine, vincristine, puromycin, daunomycin, demecolcine, and mitomycin C (Biedler & Riehm, 
1970). 
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1.3. Mechanisms of chemoresistance 
So far, many mechanisms of chemoresistance have been proposed to account for the 
phenomenon of MDR: (a) changes in the expression/function of enzymes responsible for the activation 
of pro-drugs or the inactivation of the drug; (b) a decreased uptake of chemotherapeutic drugs into the 
tumour cell, which can be due to impaired expression/function of solute carriers (SLC);  (c) an 
increased ability of the tumour cell to efflux chemotherapeutic drugs, which is mediated by efflux pumps 
belonging to the superfamily of ATP-binding cassette (ABC) proteins; (d) activation of DNA repair 
pathways; (e) changes in the expression/function of drug targets; and (f) enhanced stress responses 
(Figure 3). All these mechanisms decrease the proportion of active versus inactive chemotherapeutic 





Figure 1.4: Various mechanisms involved in tumour MDR. The major mechanisms include (a) inactivation of 
the drug (b) decreased drug uptake (c) drug efflux mediated by the MDR-related transporters, (d) increased DNA 















1.3.1. Drug efflux  
Among the mechanisms that mediate drug resistance, the most widely implicated and studied 
mechanism of MDR is drug transport through the membrane, due to the fact that tumour cells 
overexpress transporter proteins located in the cytoplasmic membrane resulting to a lower intracellular 
drug concentration (Dei et al., 2019). 
The human ATP-binding cassette (ABC) transporters, a large group of membrane protein 
complexes, consist of 49 known genes that can be grouped into at least seven family members of 
transporters (ABCA to ABCG) based on their sequence similarities. These ABC transporters have an 
important cellular role in the efflux of several substrates necessary to the cell homeostasis and also in 
the efflux of endogenous and exogenous molecules. Of them, the main ABC superfamily transporters 
involved in MDR development are multidrug resistance-associated protein 1 and 2 (MRP1/ABCC1 and 
MRP2/ ABCC2), breast cancer resistance protein (BCRP/MXR/ABCG2) and P-glycoprotein (P-gp) or 
MDR1 (multidrug resistance protein 1), the product of ABCB1 gene, located on chromosome seven 
(7q21-1), which is the most prevalent transporter associated with breast cancer drug resistance 
phenotype (Armada et al., 2016; Z. Chen et al., 2016; Daniel, 2016; Marquette & Nabell, 2012). 
ABCB1, the first member of ABC transporters, was identified in 1976 as a 170-kDa membrane 
glycoprotein overexpressed in colchicine resistant cell lines and was referred to as a glycoprotein that 
reduces drug permeability (Juliano & Ling, 1976).  In general, patients with increased expression and 
activity of ABCB1 have frequently chemotherapeutic failure and a poorer prognosis. This protein 
mediate the transport of several cytotoxic drugs associated with the MDR phenotype, such as 
anthracyclines (doxorubicin, daunorubicin), epipodophyllotoxins (etoposide and teniposide), taxanes 
(paclitaxel), vinca alkaloids (vinblastine, vincristine), anthracenes (bisantrene and mitoxantrone), and 
camptothecins (topotecan) (Armada et al., 2016). 
The relationships between ABC efflux transporter expression and tumour drug responses 
have been well established for many years, so it sparked the hope that this insidious form of resistance 
in human tumours could be eradicated. Indeed, this triggered an ongoing search for pump modulators 
that co-administered with anticancer drugs could reverse the MDR phenotype (Dei et al., 2019; Scotto, 
2003).  
Three generations of inhibitors of P-gp have been examined in preclinical and clinical studies.  
Verapamil was the first compound described to be capable to reverse drug resistance in leukaemia 
cells, demonstrating P-gp modulating activity (Tsuruo, Lida, Tsukagoshi, & Sakurai, 1981). This and 
other well-known molecules, including quinine and cyclosporine A, represent the first generation of P-
gp modulators. Unfortunately, many of them were also substrates for P-gp, thus, the use of high doses 
of the first-generation Pg-p inhibitors needed to attenuate the activity of Pg-p were ineffective or 
produced toxic side effects (Szakács, Paterson, Ludwig, Booth-Genthe, & Gottesman, 2006).  
The second generation of P-gp modulators were designed to reduce the toxicity of the first 
generation by modifying the structures of P-gp modulators belonging to the first generation. 
Unfortunately, these modulators remained P-gp substrates themselves and their P-gp inhibitory dose 
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was far beyond the tolerable dose levels (Srivalli & Lakshmi, 2012). 
The third generation of P-gp modulators included 10-fold more potent compounds when 
compared to the first and second generations.  Laniquidar (R101933), ONT-093 (OC14-093), 
zosuquidar (LY335979), elacridar (GF120918 or GW120918), and tariquidar (XR9576) where highly 
specific to ABC transporters and show a limited CYP3A inhibition, some of them have reached pre-
clinical or clinical stages. Unfortunately, clinical trials suggested that the activities of anticancer drugs 
were not improved by co-administration of these compounds, and none of them has been approved 
for therapy (Dei et al., 2019).  
These trials demonstrated that MDR is much more complex than initially believed. Increasing 
drug accumulation by inhibiting ABC transporters may have no benefit if other mechanisms of drug 
resistance are equally important. Therefore, new and innovative strategies need to be developed. 
 
1.4. miRNAs 
MicroRNAs (miRNAs) are a class of non-coding and highly conserved RNA molecules 
(ncRNA), that bind to the 3’-UTR region of mRNA by complementary base pair and negatively regulate 
its expression. Due to their small size (22-25 nucleotides), miRNAs can bind to several different 
mRNAs, while the same mRNA can be targeted by several miRNAs. More than two thousand human 
miRNAs have been identified thus far (Gomes, Rueff and Rodrigues, 2019).  It is now considered that 
most protein-coding genes are regulated by miRNAs, and it has been demonstrated that the miRNAs 
play an important role in many diverse biological processes such as cell proliferation, cell 
differentiation, stress response, metabolism and oncogenesis (Campos-parra et al., 2017; Gomes et 
al., 2016b).  
 
1.4.1. miRNAs biogenesis and target regulation  
The biogenesis of miRNAs is a complex process that takes place in the nucleus and in the 
cytoplasm. The primary miRNA (pri-miRNA) is transcribed by RNA polymerase II/III, which, after 
nuclear cleavage by DROSHA (Double-Stranded RNA-Specific Endoribonuclease) and its cofactor 
DGCR8 (DiGeorge Syndrome Critical Region Gene 8), gives rise to a 60–70 nucleotide long hairpin 
structure named pre-miRNA (Figure 4). This pre-miRNA is actively transported from the nucleus to the 
cytoplasm by exportin 5 (XPO5) where it is processed by another RNase type III enzyme, DICER, and 
its cofactor TRBP, producing miRNA duplexes (Figure 4). Subsequently, the two strands are separated 
by an RNA helicase and one of them is integrated into the RISC (RNA-induced silencing complex) 
together with an Argonaute (AGO) protein. Usually, the other strand is discarded from the complex 
(Figure 4). In addition, there are also a non-canonical miRNA biogenesis pathway, which is DROSHA 
independent and generated via pre-mRNA splicing and from small nucleolar RNA (snoRNAs) 
precursors. Depending on the target recognition, gene repression can be by mRNA cleavage, if perfect 
pairing of the miRNA-mRNA exists, or translational repression followed by mRNA degradation, when 
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imperfect pairing of the miRNA-mRNA complex occurs (Figure 4) (Campos-parra et al., 2017; Daniel, 
2016; Michlewski & Cáceres, 2019). 
 
Figure 1.5: miRNAs biogenesis. miRNAs genes are transcribed into pri-miRNA transcripts that undergo 
processing by Drosha complexes. The resulting hairpin precursor, pre-miRNAs, are transported to the cytoplasm 
by XPO5. At the cytoplasm, the Dicer complex eliminate the loop region from pre-miRNAs, and one strand of the 
resulting duplex bound to Argonaute, which depending on the target recognition, gene repression can be by 
mRNA cleavage or translational repression followed by mRNA degradation. Adapted from (Daniel, 2016). 
 
1.4.2. Deregulation of miRNAs in cancer 
In the past years it became evident that the expression of miRNAs differs between normal and 
tumour cells. Many of these miRNAs can contribute to the cancer phenotype by suppressing the 
expression of tumour suppressor genes, these miRNAs are labelled oncomiRs, or they can repress 
the cancer phenotype when downregulating oncogenic genes, labelled tumour suppressor miRNAs. 
Curiously, some miRNAs can act as both suppressors and oncogenes, depending on the cell 
microenvironment (Campos-parra et al., 2017; Daniel, 2016; Svoronos, Engelman, & Slack, 2016). 
Approximately 50% of all human miRNA genes are located in fragile regions or cancer-related 
genomic regions such as minimal regions of deletion, amplification and translocation breakpoints. If 
chromosomal regions encompassing oncogenic miRNAs may be amplified, this will result in the 
increased expression of the oncomiRs, and if the tumour-suppressive miRNAs could reside in fragile 
sites characterized by deletions or mutations, this will lead to reduced levels of these miRNAs, thus 
contributing to the development and progression of the cancer (Daniel, 2016; Giovannetti, Erozenci, 
Smit, Danesi, & Peters, 2012; Yang et al., 2013). In summary, the balance between mRNA and 
miRNAs is important, to keep mRNA abundance under control, in order to ensure correct protein 
expression. However, tumour cells acquire mechanisms that downregulate tumour suppressor 
 
10  
miRNAs and up-regulate the oncomiRs (Campos-parra et al., 2017; Daniel, 2016). 
 
1.5. MiRNA and chemotherapeutic resistance 
To date, several studies have been published showing that drug resistance is influenced by 
miRNAs (Armada, Gomes, Viveiros, Rueff, & Rodrigues, 2019; Dehghanzadeh, Jadidi-Niaragh, 
Gharibi, & Yousefi, 2015; Haenisch, Werk, & Cascorbi, 2013; Ikemura, Iwamoto, & Okuda, 2014). 
Various miRNAs have been reported to have a direct or indirect role in the regulation of the expression 
(Haenisch et al., 2013; Yang et al., 2013; Zhu et al., 2008)  or activity (Yano, Tomono, & Ogihara, 
2018) of ABCB1 in drug resistance. Most of these miRNAs are downregulated in tumour cells, which 
in turn increases the expression of ABCB1 and consequently enhances drug resistance (Kovalchuk et 
al., 2008). In a lesser number, other miRNAs might be upregulated in MDR cells and be involved in 
the overexpression of ABCB1, which contribute to the MDR phenotype in cancer cells (Zhu et al., 
2008).   
The mechanisms through which miRNAs modulate the MDR is not only by overexpression of 
ABCB1 transporters. As we described in figure 3, MDR could also arise from dysfunctional apoptosis, 
alterations in drug target and drug metabolism, increased DNA repair and decreased uptake of the 
drug. During the last decade, there has been an increasing interest in the role of miRNAs in these 
mechanisms of MDR (Dehghanzadeh et al., 2015; Drayton et al., 2014; Haenisch et al., 2013; Xu et 
al., 2011; Yu, 2009).  
Due to miRNAs’ broad spectrum and potential clinic applications, miRNAs may not only be 
used as disease biomarker, they could also represent a molecular biomarker capable of predicting the 
response to the drug provided (Campos-parra et al., 2017; Gomes et al., 2016b).  
 
1.6. Aims 
Several groups have developed cell lines resistant to specific cancer therapeutics, such as 
doxorubicin, or paclitaxel, to study biomarkers of drug resistance(G. Chen, Zhao, Zhou, Liu, & Yang, 
2010; Zhu et al., 2008). However, the time dependent assessment of the mechanisms involved during 
the development of drug resistance has not been frequently held. Furthermore, another issue that has 
not been addressed is the mechanism underlying the loss of resistance to therapy once the selective 
pressure to maintain drug resistance was withdrawn.  
The first aim of this project was to evaluate the influence of doxorubicin in drug resistance, 
especially, in ABCB1 transporter expression. Therefore, we have used the KCR cell line, a cell line 
resistant to doxorubicin due to the overexpression of ABCB1. In order to drop this resistance, KCR 
cells would be cultured without DOX for 16 weeks. Cell viability would be monitored through 
colorimetric assays in order to analyse the resistance of the cells as weeks goes by. Functional assays 
to evaluate ABCB1 activity would be performed by fluorescence microscopy and by flow cytometry to 
verify ABCB1 activity, and ABCB1 protein expression and ABCB1 mRNA would be analysed by 
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western blot and real-time qPCR.  
    The second aim of this project was to determine a signature of miRNAs that might modulate 
drug resistance mechanisms and use it as a biomarker for drug resistance, or even as a novel target 
on breast cancer therapy. Thus, once the drop of resistance is verified, 1008 miRNAs would be profiled 











































































































Chapter 2. Material and Methods 
2.  
2.1. KCR Maintenance: 
In this work we have used the KCR cell line, which is a DOX-resistant subline of Human breast 
adenocarcinoma cell lines MCF-7. They were kindly provided by Professor Joseph Molnar, Szeged 
Foundation for Cancer Research, Hungary (Kars et al., 2006). KCR cells were cultured in flasks with 
RPMI 1640 medium (Gibco, USA) with 10% foetal bovine serum (FBS) (Sigma-Aldrich #F7524, 
Darmstadt Germany) and 1% penicillin-streptomycin (with 10,000 units penicillin and 10 mg 
streptomycin per mL) (Sigma-Aldrich #P0781, Darmstadt Germany). When confluence of the flask 
reaches approximately 80% (three times a week) they were subcultured by trypsinization: with 10 % 
trypsin solution (Sigma-Aldrich #T4549, Darmstadt Germany) and 90% versene plus sodium 
bicarbonate (sodium bicarbonate 8.4% BRAUN #304494, Kronberg, Germany). When the cells were 
in suspension, in order to stop the action of trypsin, was added medium and they were centrifugate at 
800rpm for 5 minutes. Then, cells were subcultured in a new flask and incubated at 37 ºC in a 
humidified 5% CO2 chamber.  
KCR cells need to be cultured in medium with and without 1 µM of DOX (MEDAC; Germanyfor) 1 
week each in order to maintain the resistant phenotype (Gopisetty et al., 2019). To reverse this 
resistance, the drug resistant cells were cultivated without DOX for 16 weeks, losing the drug-
resistance over time, as the selective pressure to maintain drug resistance was withdrawn. Different 









Figure 2.1: Graph of Material and Methods used over the weeks. FM* Fluorescence Microscopy; FC** Flow cytometry; 
DE*** differently expressed 
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2.2. Cell viability (MTT assay) 
Cell viability was assessed using the Methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay 
(Sigma-Aldrich # M5655). Metabolically active mitochondrial dehydrogenases convert the tetrazolium 
salt MTT into insoluble purple formazan crystals at a rate that is proportional to cell viability. 
Approximately 10000 cells/well were cultured in complete medium in 96-well plates. The cells were 
allowed to grow for 24 h. Next, the medium was removed and was added 150 μL of medium with 
different concentrations of DOX (0, 0.15, 0.3, 0.6, 1.25, 2.5, 5, 10 and 20 μM) for 72 h. After these, 
MTT was added to each well at a final concentration of 0.5 mg/mL. Cells were then incubated for 4 h 
and 100 μL of sodium dodecyl sulphate (10% SDS in 0.01 M HCl, Sigma-Aldrich) was added to each 
well to dissolve the formazan crystals and incubated overnight. Absorbance was read at 570 nm in a 
microplate reader SpectraMax i3x. This assay was performed for KCR cells over time, as the selective 
pressure to maintain drug resistance was withdrawn, specifically in 0, 4, 6, 10, 15 and 16 weeks, 
obtaining different cell viability curves.  
 
2.3. Evaluation of ABCB1 activity by fluorescence microscopy 
ABCB1 activity was measured by fluorescence microscopy as previously described with minor 
modifications (Armada et al., 2019). Cells were seeded on sterilized glass coverslips in 24-well culture 
plates at a density of 2 × 105 cells/ml and allowed to grow overnight at 37 ºC. In the next day, medium 
was removed from wells and fresh medium with and without 10 µM verapamil (VP; Sigma-Aldrich) was 
added to each duplicated experiment well and incubated for 30 minutes before addition of 1 µg/ml of 
DiOC2 (Molecular ProbesTM, USA) for 1 h at 37 ºC. Subsequently, medium was removed, and dye free 
medium was added with the presence or absence of VP for another 1 h. Slides were rinsed twice in 
cold PBS (pH 7.4) and then cells were examined using a fluorescence microscopy. Cells were 
examined at 485 nm excitation laser and 530/30 nm emission filter (green fluorescence). This 
experiment was done using KCR parental cell line (week 0) and KCR with DOX withdrawal for 9 and 
16 weeks. 
 
2.4. Evaluation of ABCB1 activity by flow cytometry 
Flow cytometry was performed according to (Armada et al., 2019) with minor modifications. 
Briefly, cells were harvested by trypsinization, resuspended in complete medium and cells were 
quantified by direct microscopy, using a Neubauer-chamber. Cells were placed in 1.5 mL tubes at a 
concentration of 2 × 106 cells/ml and pre-incubated in medium (control cells) or treated with 10 µM VP, 
for 30 min at 37 ºC. Then DiOC2 (1 µg/ml) was added and cells were incubated for 1 h at 37 ºC. Then, 
cells were centrifuged 10 min at 2000 ⨯ rpm and to keep efflux pumps inhibited, cells were 
resuspended in 500 µl of fresh medium in the presence or absence (in the control cells) of VP and 
incubated for another hour at 37 ºC. Cells were washed twice with cold PBS (pH 7.4), resuspended in 
500 µl cold PBS (pH 7.4) and fluorescence retention was measured by flow cytometry, using FACS 
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CANTO IITM (BD Biosystem, Franklin Lakes, New Jersey). Data was collected for at least 40,000 
events per sample and processed with the FlowJoTM10 software. This experiment was done using 
KCR parental cell line (week 0) and KCR with DOX withdrawal for 9 and 16 weeks. 
 
2.5. ABCB1 protein expression by Western Blot 
2.5.1.  Purification of membrane proteins 
Cells were harvested by trypsinization, and the membrane proteins were isolated by using 
Mem-PERM Membrane Protein Extraction Kit according to the manufacturer instructions (Thermo 
Fisher). Briefly, 5 x 106 cells were washed twice with Cell Wash Solution, and centrifuged 5 minutes 
at 300 x g. Then, cells were resuspended in 750µL of Permeabilization Buffer, and incubated 10 
minutes at 4°C with constant mixing. Permeabilized cells were centrifuged 15 minutes at 16,000 × g. 
500 µL of Solubilization Buffer was added to pelleted cells and resuspended by pipetting up and down. 
Then, cells were incubated at 4°C for 30 minutes with constant mixing. Finally, cells were centrifuged 
at 16000 x g, for 15 minutes at 4ºC and the supernatant collected and stored at -80°C. 
 
2.5.2. Western Blot 
Prior to western blot, membrane proteins were quantified using the Bradford Method 
(Bradford, 1976). A Bovine Serum Albumin (BSA) solution of 2 mg/ml (Bio-Rad) was used to prepare 
a calibration curve, with different dilutions (0 µg, 0.25 µg, 0.5 µg, 1 µg, 1.25 µg, 2 µg, 2.5 µg, 5 µg, and 
10 µg). Our samples (KCR week 0, 10 and 15) were diluted in 1:400 ratio in deionized water. After 
this, the Bradford reagent was added in 1:5 ratio. Samples absorbance were read in a 96-well plate at 
570 nm (Biotrak II Plate reader, Amersham Biosciences, Germany).   
For western blot, protein samples were denaturated in Laemmli buffer 2⨯ (4% (w/v) SDS 10%; 
20% (v/v) glycerol 50%; 0.02% (w/v) bromophenol blue; 125 mM Tris-HCl pH 6.8; and 10% (v/v) 2-
Mercaptoethanol) in a proportion of 1:1 and heated at 95 °C for 5 minutes. Samples were then loaded 
into a 10% sodium dodecyl sulfate-polyacrylamide gel and subject to electrophoresis at 100V for 90 
minutes in running buffer 1⨯ (stock solution: 25 mM Trizma-base; 192 mM Glycine; 0.1% (w/v) SDS; 
pH 8.3). The gels were incubated in transfer buffer 1⨯ (stock solution: 25 mM Trizma.base; 192 mM 
Glycine; 0.1% (w/v) SDS; and 10% methanol) for 20 minutes as well as the Immun-Blot PVDF 
membrane for protein blotting – 20 µm pore size (BioRad). Next, proteins were transferred from gel to 
PVDF membrane in transfer buffer 1⨯ for 60 minutes at 100 V. Membranes were then blocked using 
blocking buffer from WesternDotTM 625 Goat Anti-Mouse Western Blot Kit (Invitrogen) for 1 hour. The 
membranes were probed overnight at 4ºC with anti-human ABCB1 (dilution 1:1000) (D11: sc-55510, 
Santa Cruz Biotechnology) and Na+/K+-ATPase β1 (dilution 1:1000) (C464.8: sc-21713, Santa Cruz 
Biotechnology). Then, membranes were washed three times with wash buffer 1⨯ and incubated at 
room temperature for one hour with anti-mouse secondary antibody (dilution 1:1000) (Invitrogen). At 
last, and after three more washes, the membranes were incubated at room temperature with Qdot® 
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625 streptavidin for one hour (dilution 1:2000) (Invitrogen). The membranes were then visualized under 
ultra-violet light and captured by ChemiDocTM Touch Imaging System (Bio-Rad, USA). In order to 
quantify the differences obtained we used Image Lab software version 5.2.1 (Bio-Rad). 
 
2.6. Total RNA purification 
Total RNA (including miRNAs) from KCR cells were purified with miRNeasy Mini kit (Qiagen, 
#1038703, Germany), accordantly to what is described by the manufacture. Briefly, 6x106 cells were 
harvested and lysed in 700 µl of RLT plus β-mercaptoethanol and conserved at -80ºC until further use. 
350µl of the lysate was diluted in a proportion of 1:2 with Acid Phenol:Chloroform (5:1 Solution pH 4.5; 
Ambion), mixed vigorously and stored 5 min at room temperature. Next, lysate was centrifuged for 15 
min at ≥12000 ⨯ g at 4ºC. The aqueous phase (containing RNA) was carefully removed and placed in 
a new tube.  After this, 100% ethanol was added in a proportion of 1:1.5 to the aqueous phase and 
mixed by pipetting. This solution was loaded into a RNeasy Mini column and centrifuged for 15 min at 
≥12000 ⨯ g at room temperature. The flow-through was discarded and the RNeasy Mini column was 
washed by adding 700 µl of RWT buffer and centrifuged for 15 s at ≥8000 ⨯ g. The flow-through was 
discarded. A second wash with 500 µl of RPE buffer was done, followed by a centrifugation for 15 s at 
≥8000 ⨯ g. The flow-through was also discarded. A third wash with 500 µl of RPE buffer was done, 
followed by a centrifugation for 2 min at ≥8000 ⨯ g. The flow-through was again discarded. Next, a 
new centrifugation was done for 1 min at ≥8000 ⨯ g at room temperature and 40 µl of nuclease-free 
water was added directly to the spin column membrane, store 5 minutes at room temperature and 
centrifuged for 1 min at ≥8000 ⨯ g to elute the RNA. This RNA was then stored at -80 °C until further 
use. All samples were quantified and purity ratios 260/280 and 260/230 were determined by using 
nanodrop spectrophotometer. 
 
2.7. Real-time qPCR quantification of ABCB1 mRNA 
Relative quantification of ABCB1 mRNA was carried out as published before (Armada et al., 
2019). Briefly, cDNA was synthesized from 1μg of total RNA using the High Capacity cDNA Reverse 
Transcription Kits (Applied Biosystems) in a final reaction volume of 20μL according to the 
manufacturer’s instructions. For relative quantification was used a QuantStudio 5 Real-Time PCR 
System (Applied Biosystems) and pre-developed Taqman® primer assays were purchased to Applied 
Biosystems (ABCB1, Hs00184491_m1 and the human GAPDH, 4352934E as the reference gene). All 
PCR reactions were done in a total volume of 10 μL by using TaqMan® Taqman Universal PCR Master 
Mix (Applied Biosystems). Template controls and reverse transcriptase controls (RT negative) for each 
cDNA synthesis were included. Thermal cycler conditions were 50 °C for 2 min; 95 °C for 10 min 
followed by 40 cycles at 95 °C for 15 s and at 60 °C for 1 min. The mean values of the triplicate RT-
qPCR reactions for each assay were normalized with the expression values for each gene. Relative 
expression of ABCB1 was performed by the comparative 2-(ΔΔCt) method. 
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2.8. Real-time qPCR quantification of miRNAs 
The relative expression of 1008 miRNAs in KCR parental cells (week0) and KCR cells week 
16 were quantified by using miScript II RT Kit and Human miRNome miScript® miRNA PCR Array 
from Qiagen (MIHS-216ZA) in QuantStudio 5 Real-Time PCR System (Applied Biosystems) according 
to the protocol described by the manufacturer. Briefly, miRNA was converted into cDNA using miScript 
II RT Kit. In PCR tubes a master mix was prepared with the supplied 5⨯ miScript Hispec buffer reaction 
buffer, 10⨯ miScript Nuleics Mix, miScript reverse transcriptase Mix and RNase-free water. Total RNA 
was added in the last in order to achieve a working amount of 1500 ng in a 20 μl volume. The cDNA 
synthesis was performed according to the following steps: initial step at 37 °C for 60 minutes and 
second step, enzyme inactivation, at 95 °C for 5 min. In the end, was added 310 μl of RNase-free 
water to the 20μl of cDNA, divided in 3 aliquots of 110 μl each and stored at -20 ºC until further use.  
Then, a real-time qPCR reaction mix was prepared with 1375 μl of 2⨯ QuantiTect SYBR® 
Green PCR Mastermix buffer, 275μl of 10⨯ miScript Universal Primer, 1075 μl of RNase-free water 
and 25 μl of cDNA. From this mixture, 25 μl was added to each well in a 96-well plate containing 
microRNAs primers. A centrifugation was done for 1 min at ≥1000 ⨯ g at room temperature. Thermal 
cycler conditions were 15 min at 95 ºC, followed by 40 cycles for 15 s at 94 ºC, 30 s at 55 ºC and 30 s 
at 70 ºC, with a melting curve in the end. The relative expression of miRNAs was performed by the 
comparative 2-(ΔΔCt) method. 
 
2.9. Pathway analysis of miRNA target genes 
The DIANA-miRPath v3.0 web server (Vlachos, Zagganas, et al., 2015) was used for the 
identification of miRNA target genes, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways 
(Kanehisa, Sato, Furumichi, Morishima, & Tanabe, 2019) and Gene Ontology (GO) terms (Ashburner 
et al. 2000; The Gene Ontology Consortium 2019). miRNA target genes were identified using 
experimentally validated interactions contained in Tarbase v7.0 (Vlachos, Paraskevopoulou, et al., 
2015). The “Genes intersection” method was used for pathway analysis and GO terms enrichment. An 
intersection set composed of 3 miRNAs was used, i.e., all genes targeted by at least 3 miRNAs 
contained in the selected set was used for enrichment analysis. The p-value threshold was of 0.05. 
Advanced statistic options included “FDR Correction”.  
 
2.10. Statistical analysis 
Data were analysed with GraphPad Prim® 5.01 for Windows. Values are presented with an 
approximate mean ± standard error of the mean (SEM) or mean ± standard error (SD). In the MTT 
assay, the statistical analysis was performed based on 2-way ANOVA with Bonferroni’s post-test. In 
the Quantification of cellular DiOC2 retention (median fluorescence intensity) by flow cytometry, the 
statistical analysis was performed based on One-way ANOVA analysis with Bonferroni's Multiple 
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Comparison Test. In the analysis of ABCB1 gene expression, the statistical analysis was performed 





























Chapter 3. Results 
 
3.1. Viability of the DOX-deprived KCR cells over time 
The MTT assay is a colorimetric assay used to assess cytotoxicity and cell viability. MTT is a 
monotetrazolium salt that when entering the cells is reduced by NAD(P)H-dependent oxidoreductases 
and dehydrogenases of metabolically active cells to form purple MTT-formazan. This allows a 
correlation between the colour intensity of the formazan dye and the number of viable cells. The cells 
were allowed to grow for 24 h. Next, the medium was removed and was added 150 μL of medium with 
different concentrations of DOX (0, 0.15, 0.3, 0.6, 1.25, 2.5, 5, 10 and 20 μM) for 72 h. 
As stated previously, eight different concentrations (0.15 µM, 0.31 µM, 0.63 µM, 1.25 µM, 2.5 
µM, 5 µM, 10 µM and 20 µM) of DOX were tested in six different weeks after DOX withdrawal, (week 
0, 4, 6, 10, 15 and 16). Cells were treated with DOX at indicated concentration for 72 h. Each assay 
had a negative control (NC) in which the cells weren’t exposed to any concentration of DOX. Since the 
negative control was not exposed to any concentration it was associated with 100% of cell viability 
(Figure 3.1. (A)). In this assay, it is possible to observe a decrease of cell viability over time. When we 
compare week 0 with all other weeks tested, we observe a statistically significant decrease in week 
10, week 15 and week 16, in the following concentrations of DOX: 2.5 µM, 5 µM, 10 µM and 20 µM 
(Fig. 3.1. (B)). When we look to higher concentration of DOX, 20µM, it is possible observe a 40% drop 









Figure 3.1: MTT assay for DOX in KCR cells at week 0, 4, 6, 10, 15 and 16. (A) Effects of doxorubicin on cell viability 
of KCR cells. In this experiment, cells were treated with doxorubicin at indicated concentration for 72H. (B) Plot of 
statistically relevant results. Statistical analysis was performed based on 2-way ANOVA with Bonferroni’s post-test. 
Statistical significance was considered when p < 0.05.  
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3.2. Activity of ABCB1 in DOX-deprived KCR cells over time 
3.2.1 Fluorescence microscopy efflux assay 
It has been demonstrated that an increased expression and function of the ABCB1 efflux pump 
is related to drug resistance. The parental KCR cells (week 0), overexpressed ABCB1 efflux pumps, 
this is the principal phenotype responsible for the drug resistance observed in this cell line. To evaluate 
the efflux activity of ABCB1, we use VP, a synthetic known inhibitor of ABCB1, and DiOC2 which bind 
specifically to mitochondria of living cells and is a specific fluorescence substrate of ABCB1.  
In this methodology, through fluorescence microscopy we analysed KCR cells on week 0, 9 
and 16, by exposing them to the DiOC2 with or without inhibitor (Figure 3.2). VP was used as a positive 
control, since, in the presence of this inhibitor the ABCB1 pumps are blocked. Therefore, the cells will 
retain the DiOC2 and become fluorescent. On the other hand, when we add DiOC2 to the cells without 
VP, the efflux pumps will extrude the DiOC2 and the cells become less fluorescent.  
Looking to the cells without VP in the Figure 3.2 (left), we can observe an increase of 
fluorescence when we compare parental KCR cells (week 0) with KCR week 9 and a more accentuated 
increase is observed when we compare with KCR week 16. This demonstrates that KCR week 0 have 
more efflux activity than KCR week 9 and KCR week 16. Therefore, KCR cells are losing the activity 






























































 Figure 3.2: ABCB1 activity verified by fluorescent microscopy (200x magnification) after treatment with 
DiOC2 and verapamil (10 µM and 20 µM) as positive control. In the figure we can see an accumulation of DiOC2 
inside the cells as time goes by, meaning that cells had a loss of ABCB1 activity. Green colour reflects the 
accumulation of DiOC2 inside the cell. 
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3.2.2 Fluorescent substrate efflux assay by flow cytometry 
Since fluorescence microscopy is a qualitative analysis, we performed a fluorescent substrate 
efflux assay by flow cytometry to quantify the differences observed in Figure 3.2. As we did in 
fluorescence microscopy, this method was performed with the KCR cells on week 0, 9 and 16, also 
exposing them to the DiOC2 with or without inhibitor. Once again, VP was used as a positive control 
in this assay.  
An example of the gating process of the unstained (negative control) of KCR cells in week 0 
is represented in Figure 3.3. Forward scatter area (FSC-A) vs side scatter-area (SSC-A) density plot 
was used to remove debris and pyknotic cells in the lower left-hand portion of the plot as well as the 
very large (off scale) debris found in the upper right-hand portion (Figure 3.3). Singlet gate was used 
to define the non-clumping cells based on pulse geometry forward scatter height (FSC-H) vs FSC-A 
eliminating the doublets (Figure 3.3). Then, gated cells corresponding to viable KCR cells were 
represented on one-parameter histogram by plotting FITC-A/DiOC2 vs the number of events (Figure 
3.4 (A)). Data analysis was performed using FlowJo, that allowed to determine the Median, Mean and 
SD of fluorescence intensity inside the cells, which represent the percentage of DiOC2 retention. 
 Subsequently, the median of the fluorescence intensity inside the cells without VP, was 
translated into the graph in Figure 3.4. (A). We can observe that there was an increase of the 
fluorescence on KCR week 9 and a significant increase on KCR week 16, when compared with the 
parental cells, KCR week 0. Since more accumulation indicates less efflux of ABCB1 efflux pumps, 
these results indicate once more that the activity of ABCB1 efflux pumps in KCR cells was significantly 
diminished in KCR week 16 compared with KCR week 0. In Figure 3.4. (B) we show the results from 
Figure 3.4. (A) expressed as the median ± SEM and showing the statistical difference between KCR 


























Figure 3.3: Gating of an unstained of KCR cells to select the population of interest through flow 
Figure 3.4: ABCB1 activity measured by flow cytometry after treatment with DiOC2. (A) Representative 
fluorescent intensity histogram in week 0 (red), week 9 (blue) and week 16 (orange). We can see an increase in 
fluorescent intensity as time passes, meaning that less ABCB1 membrane transporters are active in week 16. In 
(B) we show the results expressed by fluorescent means of two independent assays. Data are expressed as the 
median ± SEM. Statistical significance was considered when p < 0.05. 
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3.3. ABCB1 expression in DOX-deprived KCR cells 
The expression of ABCB1 was evaluated in cell lysates of KCR week 0, 10 and 15 through 
western blot and in KCR week 0 and 16 through real-time qPCR. 
As illustrated in Figure 3.5 (A), ABCB1 protein expression has a marked decrease over time. 
Through densitometry, we detected an approximately 10% decrease in week 10 and 40% decrease in 
week 16 of ABCB1 transporter. The results obtained from these assays demonstrate that the reduced 
activity of ABCB1 efflux pump observed by flow cytometry and microscopy is due to a lower expression 
of ABCB1 pumps. By RT-qPCR, we also showed a 9.3-fold decrease of ABCB1 mRNA expression in 
KCR week 16 compared to KCR week 0 (Figure 3.3 (B)). We tested (Na+/K+ -ATPase β1) as a loading 
control and it was poorly detected in these samples, for reasons we could not control, possibly the 
specificity of the antibody. Therefore, a Bradford was done with an R2 = 0.9917, which indicates that 
the loaded protein concentration was correctly quantified, and the same amount of protein was added 
to the gel. We also performed a Coomassie Brilliant Blue staining to verify the integrity of the proteins 
















Figure 3.5: Expression levels of ABCB1 in KCR cells. (A) Western blot analysis for protein expression of 
ABCB1 in KCR cells. Values are means of two independent experiments expressed as the mean ± SEM. Data 
was normalized against total proein determine by densiometric analysis using image J. We can observe a 
decrease as time passes of ABCB1 protein expression. (B) Relative expression of ABCB1 gene assessed by 
real-time qPCR. The values showed represents 3 independent experiments using 2-(ΔΔCt) method. ABCB1 
expression was normalized to the house keeping gene GAPDH. Here we showed a decrease of 9.3-fold change 
of ABCB1 mRNA expression between KCR week 0 and 16. Means were significantly compared to the control 




























p < 0.05 
** 
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3.4. miRNAs differently expressed in DOX-deprived KCR cells 
In order to identify miRNAs differentially expressed after 16 weeks without DOX, we quantified 
the relative expression of 1008 miRNAs of KCR week 0 and KCR week 16. We used the control miRTC 
and the equation 2-ΔCT. 
Considering just the miRNAs with a fold-change higher than 2, 23 miRNAs were found 
differentially expressed in the KCR cells after 16 weeks without DOX. Thirteen of these miRNAs were 
under expressed, with hsa-miR1287-5p showing the highest fold-change value (-7-fold) (Table 1). 
Futhermore, 10 miRNAs were over expressed, with hsa-miR-183-3p displaying the highest fold-
change value (4.7-fold) (Table 1). 
 
Table 3. Twenty-three miRNAs differentially expressed in KCR cells after 16 weeks without DOX, 
compared to parental KCR cells (week 0). microRNAs were selected by fold-change ≥ 2 Thirteen were 
downregulated while ten were over-expressed. 
KCR week 16 





Under-expressed hsa-miR-585-3p MIMAT0003250 -2.8 
 hsa-miR-34a-5p MIMAT0000255 -3.3 
 hsa-miR-877-5p MIMAT0004949 -3.9 
 hsa-miR-1287-5p MIMAT0005878 -7.0 
 hsa-miR-1182 MIMAT0005827 -2.3 
 hsa-miR-155-3p MIMAT0004658 Only expressed in KCR week 0 
 hsa-miR-656-3p MIMAT0003332 -2.1 
 hsa-miR-323b-5p MIMAT0001630 -3.0 
 hsa-miR-4304 MIMAT0016854 Only expressed in KCR week 0 
 hsa-miR-3691-5p MIMAT0018120 -4.6 
 hsa-miR-676-5p MIMAT0018203 -2.4 
 hsa-miR-4258 MIMAT0016879 Only expressed in KCR week 0 
 hsa-miR-3177-3p MIMAT0015054 -5.3 
Over-expressed hsa-miR-635 MIMAT0003305 
Only expressed in KCR week 
16 
 hsa-miR-502-5p MIMAT0002873 4.1 
 hsa-miR-342-3p MIMAT0000753 3.1 
 hsa-miR-767-5p MIMAT0003882 2.3 
 hsa-miR-1307-3p MIMAT0005951 2.7 
 hsa-miR-1207-5p MIMAT0005871 
Only expressed in KCR week 
16 
 hsa-miR-548k MIMAT0005882 
Only expressed in KCR week 
16 
 hsa-miR-183-3p MIMAT0004560 4.7 
 hsa-miR-1193 MIMAT0015049 
Only expressed in KCR week 
16 
 hsa-miR-187-5p MIMAT0004561 





3.5. Functional pathways and gene ontology analyses 
In order to identify functional pathways associated with the miRNAs in Table 3 we used 
DIANA-mirPath, a miRNA pathway analysis webserver that allows an enriched analysis of KEGG 
categories and GO terms (Vlachos, Paraskevopoulou, et al., 2015). Thus, the KEGG categories 
identified using all miRNAs differently expressed, listed in Table 3, were “Renal cell carcinoma”,  
“Pathways in cancer”, “Proteoglycans in cancer”, “Prostate cancer”, “Viral carcinogenesis”, “Cocaine 
addiction”, “Glioma”, “Long-term depression”  and “ECM-receptor interaction” (Figure 3.6.). Since we 
are studying cancer drug resistance, we only considered the pathways “Pathways in cancer” 
(hsa05200), (Appendix, Figure A.1), “Proteoglycans in cancer”, (hsa05205) (Appendix, Figure B.1) 
and “ECM-receptor interaction”, (hsa04512) (Appendix, Figure C.1) to be analysed in detail (Table 4; 
Table 5 and Table 6).  
 
 
Figure 3.6: Gene enrichment analysis using KEGG pathways enriched with genes targeted by the 
differentially expressed miRNAs in KCR cells 16 weeks without DOX, ordered by decreasing p-value. Target 




































- Pathways in cancer 
In “Pathways in Cancer” miRNA-target gene interactions were represented according with 
Tarbase. These included 13 out of 23 miRNAs (hsa-miR-34a-5p, hsa-miR-877-5p, hsa-miR-3691-5p, 
hsa-miR-155-3p, hsa-miR-1307-3p, hsa-miR-1207-5p, hsa-miR-183-3p, hsa-miR-767-5p, hsa-miR-
187-5p, hsa-miR-635, hsa-miR-342-3p, hsa-miR-548k, hsa-miR-502-5p) and 15 putative target genes 
(CRKL, GNAS, ETS1, BCL2, CDK6, CTNNB1, E2F3, LAMC1, EP300, GNAI2, CDKN1A, ITGB1, 
NRAS, ARNT, IGF1R) (table 4).   
 
Table 4. Putative genes targeted by the differentially expressed miRNAs in KCR cells 16 weeks without 
DOX in the KEGG category “Pathways in Cancer”. 






Under expressed hsa-miR-34a-5p CRKL | GNAS | ETS1 | BCL2 | CDK6 | CTNNB1 | E2F3 
| LAMC1 | EP300| GNAI2 | CDKN1A 
 hsa-miR-877-5p ITGB1 | CRKL | ETS1 | LAMC1 
 hsa-miR-3691-5p ARNT | ETS1 | EP300 
 hsa-miR-155-3p CDKN1A 
Over expressed hsa-miR-1307-3p GNAS | BCL2 | CDK6 | CDKN1A 
 hsa-miR-1207-5p BCL2 | IGF1R | CTNNB1 | EP 300 | GNAI2 
 hsa-miR-183-3p NRAS | CDK6 | CTNNB1 | E2F3 
 hsa-miR-767-5p NRAS | EP300 
 hsa-miR-187-5p ETS1 | IGF1R | CTNNB1 
 hsa-miR-635 ITGB1 
 hsa-miR-342-3p ITGB1 | CRKL | GNAS | IGF1R | E2F3 | LAMC1 | EP 
300 
 hsa-miR-548k ARNT | CDK6 | CTNNB1 | LAMC1 









- Proteoglycans in cancer  
In “Proteoglycans in cancer” were identified 12 out of 23 miRNAs (hsa-miR-155-3p, hsa-miR-
877-5p, hsa-miR-34a-5p, hsa-miR-342-3p, hsa-miR-1207-5p, hsa-miR-187-5p, hsa-miR-1307-3p, 
hsa-miR-635, hsa-miR-502-5p, hsa-miR-767-5p, hsa-miR-183-3p and hsa-miR-548) and 6 target 
genes (CDKN1A, ITGB1, THBS1, CTNNB1, IGF1R, NRAS) (table 3).  
 
Table 5. Putative genes targeted by the differentially expressed miRNAs in KCR cells 16 weeks without 







Under expressed hsa-miR-155-3p CDKN1A 
 hsa-miR-877-5p ITGB1 
 hsa-miR-34a-5p THBS1 | CTNNB1 | CDKN1A 
Over expressed hsa-miR-342-3p ITGB1 | THBS1 | IGF1R 
 hsa-miR-1207-5p IGF1R | CTNNB1 
 hsa-miR-187-5p IGF1R | CTNNB1 
 hsa-miR-1307-3p THBS1 | CDKN1A 
 hsa-miR-635 ITGB1 
 hsa-miR-502-5p NRAS | CDKN1A 
 hsa-miR-767-5p NRAS 
 hsa-miR-183-3p NRAS | CTNNB1 













- ECM-receptor interaction 
In “ECM-receptor interaction” were identified 6 out of 23 miRNAs (hsa-miR-34a-5p, hsa-miR-
877-5p, hsa-miR-635, hsa-miR-548k, hsa-miR-342-3p, hsa-miR-1307-3p) and 3 target genes (THBS1, 
LAMC1, ITGB1) (table 4).  
 
Table 6. Putative genes targeted by the differentially expressed miRNAs in KCR cells 16 weeks without 







Under expressed hsa-miR-34a-5p THBS1 | LAMC1 
 hsa-miR-877-5p ITGB1 | LAMC1 
Over expressed hsa-miR-635 ITGB1 
 hsa-miR-548k LAMC1 
 hsa-miR-342-3p ITGB1 | THBS1 | LAMC1 

















Gene ontology (GO) 
Gene Ontology enrichment analysis showed that KCR week 16 has 9 “cellular components” 
terms associated with the dysregulated miRNAs and loss of resistance (Table 7), with the higher 
number of target genes identified in the “organelle”, “nucleus”, “protein complex” and “cytosol”. 
Although with only 3 target genes, we would like to highlight the “microRNA-RISC complex”, a known 
complex involved in miRNA dependent gene regulation. The putative targets are DICER1, AGO3 and 
AGO1. This data might justify the number of differentially expressed miRNAs. DICER1 is putatively 
regulated by hsa-miR-34a-5p, hsa-miR-877-5p, hsa-miR-342-3p, hsa-miR-1207-5p, hsa-miR-183-3p 
and hsa-miR-502-5p, as indicated by bioinformatics analysis, and AGO3 by hsa-miR-34a-5p, hsa-miR-
183-3p and hsa-miR-502-5p. AGO1 is putatively regulated by hsa-miR-34a-5p, hsa-miR-877-5p, hsa-
miR-183-3p and hsa-miR-502-5p. Gene enrichment performed analysis according to “molecular 
function” (Table 8) revealed that the dysregulated miRNAs found in KCR week 16 regulate 8 “molecular 
functions” terms, in particular “ion binding” with 72 putative targets, “RNA binding” with 45, “poly(A) 
RNA binding with 38 and “enzyme binding” with 27 targets. Although with less genes detected, we 
would like to highlight the molecular function “miRNA binding” with 3 putative targets, the same as 
detected in “microRNA-RISC complex”. We also enriched our data according to “biological process” 
terms, revealing 57 different terms (Table 9). The highest number of genes were detected in “cellular 
nitrogen compound metabolic process” with 79 genes, “biosynthetic process” with 60 genes and 
“response to stress” with 46 genes. 
 
Table 7. Gene enrichment analysis using GO “Cellular component” terms with genes targeted by the 
differentially expressed miRNAs between KCR week 0 and KCR week 16. Cellular component terms are 
ordered by increasing p value. 
 
GO - Cellular Component #genes #miRNAs 
organelle 143 13 
protein complex 73 13 
cytosol 56 13 
nucleoplasm 26 13 
cellular_component 182 13 
microtubule organizing center 12 13 
micro-ribonucleoprotein complex 3 6 
cyclin-dependent protein kinase  
        holoenzyme complex 
3 9 
nucleus 113 13 
nuclear envelope 8 10 
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Table 8. Gene enrichment analysis using GO “Molecular function” terms with genes targeted by the 
differentially expressed miRNAs between KCR week 0 and KCR week 16. Molecular function terms are 





Table 9. Gene enrichment analysis using GO “Biological Process” terms with genes targeted by the 
differentially expressed miRNAs between KCR week 0 and KCR week 16. Biological Process terms are 
ordered by increasing p value 
GO - Biological process #genes #miRNAs 
gene expression 24 11 
cellular nitrogen compound metabolic process 79 13 
response to stress 46 13 
biosynthetic process 60 13 
symbiosis, encompassing mutualism through parasitism 16 12 
mitotic cell cycle 13 13 
viral process 13 12 
cellular protein modification process 37 13 
blood coagulation 13 13 
Fc-epsilon receptor signaling pathway 7 10 
regulation of cell cycle 11 11 
immune system process 29 13 
cell cycle arrest 9 11 
platelet degranulation 5 9 
cell cycle 21 13 
intrinsic apoptotic signaling pathway 5 7 
transcription, DNA-templated 39 13 
platelet activation 7 9 
Notch signaling pathway 8 11 
regulation of transcription from RNA polymerase II promoter in response to hypoxia 3 7 
GO - Molecular Function #genes #miRNAs 
RNA binding 45 13 
poly(A) RNA binding 38 13 
Molecular_function 186 13 
enzyme binding 27 13 
ion binding 72 13 
transcription factor binding 17 12 
protein binding transcription factor activity 11 13 
translation factor activity, nucleic acid binding 5 9 
miRNA binding 3 6 
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neurotrophin TRK receptor signaling pathway 7 10 
cellular response to hypoxia 7 11 
fibroblast growth factor receptor signaling pathway 7 12 
cellular protein metabolic process 10 13 
negative regulation of translation involved in gene silencing by miRNA 3 6 
cell death 17 12 
positive regulation of protein insertion into mitochondrial membrane involved in 
apoptotic signaling pathway 
3 5 
3'-UTR-mediated mRNA stabilization 3 6 
nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay 4 9 
mRNA processing 13 11 
DNA methylation 4 7 
membrane organization 12 11 
positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-
dependent decay 
3 7 
biological_process 175 13 
organ morphogenesis 7 11 
mRNA splicing, via spliceosome 8 11 
positive regulation of nuclear-transcribed mRNA poly(A) tail shortening 3 7 
innate immune response 14 12 
mRNA metabolic process 6 9 
regulation of translation 6 9 
RNA splicing 9 11 
regulation of mRNA stability 3 6 
PML body organization 2 5 
chromatin organization 5 10 
nucleobase-containing compound catabolic process 15 12 
response to endoplasmic reticulum stress 5 9 
epithelial cell differentiation involved in prostate gland development 2 7 
nuclear-transcribed mRNA poly(A) tail shortening 3 8 
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class 
mediator 
4 9 
phosphatidylinositol-mediated signaling 5 9 
epidermal growth factor receptor signaling pathway 6 10 
catabolic process 26 13 
regulation of viral genome replication 2 6 
negative regulation of anoikis 3 8 
establishment or maintenance of microtubule cytoskeleton polarity 2 4 
T cell differentiation in thymus 4 6 
negative regulation of transcription from RNA polymerase II promoter 19 13 


























































Chapter 4. Discussion 
 
The occurrence of cancer drug resistance (CDR) is one of the main obstacles in the success of 
traditional chemotherapy treatment in cancer patients. Understanding the molecular mechanisms 
underlying drug resistance in cancer cells may aid in the design of novel strategies for overcoming 
CDR (Jinglu Wang, Seebacher, Shi, Kan, & Duan, 2017). CDR is multifactorial and may be due to 
multiple mechanisms, which enable cancer cells to survive against the harmful action of cytotoxic drugs 
(Lopes-Rodrigues et al., 2017). 
One of the most frequent CDR mechanisms is the overexpression of ABCB1 transporters 
(Lopes-Rodrigues et al., 2017). Thus, one aim of this work was to determine the influence of DOX in 
ABCB1 transporters expression. However, other important mechanisms are established in the 
development of MDR, such as the modification of drug metabolism, drug target alteration, activation of 
DNA repair mechanisms or/and apoptotic death prevention, and epigenetic phenomena. Among these 
epigenetic phenomena are the expression of miRNAs.  
miRNAs are small noncoding RNAs that modulate a great number of biological processes by 
regulating gene expression at the post-transcriptional level by mRNA cleavage or translational 
repression followed by mRNA degradation. Therefore, another aim of this work was to determine a 
signature of miRNAs that might modulate CDR mechanisms and use it as a biomarker for drug 
resistance. 
In this work, using KCR cells, a DOX-resistant subline of Human breast adenocarcinoma cell 
line MCF-7, we induced loss of drug resistance by proliferating these cells for 16 weeks without DOX in 
the culture medium. We then performed viability assays such as the MTT assay, and functional assays 
to evaluate ABCB1 activity by fluorescence microscopy and by flow cytometry. Beside these assays, we 
also analysed ABCB1 protein expression by Western Blot, and quantified ABCB1 gene by real-time 
qPCR. 
Starting with MTT assay, the objective of this assay was to determine the loss of resistance of 
the KCR cells over time, as the selective pressure to maintain drug resistance was withdrawn. As there 
are no articles in which the loss of resistance has been carried out, we did not know how long it would 
take for the cells to lose their resistance to DOX, nor did we know how much would be the decrease that 
we would be able to obtain, therefore we had to choose the concentrations that we would use. The MTT 
assay was performed at concentrations (0, 0.15, 0.3, 0.6, 1.25, 2.5, 5, 10 and 20 μM (higher 
concentration that does not interfere in) with MCF-7 cells (IC50 DOX = 0.92 μM). As KCR is a 
doxorubicin-resistant subline of MCF-7 and we wanted to have managed to reverse all the resistance 
gain, we did MTT assay with this range of DOX concentrations. Thus, we performed an MTT assay over 
time to monitor the loss of drug resistance in KCR cells, and we observed that from week 10 there is a 
statistically significant decrease of cell viability. Also, in the week 16 we observed a 40% drop of cell 
viability at 20 µM DOX (Figure 3.1). These results indicate that KCR cells are losing the ability to survive 
against DOX, which means they are losing their resistance to DOX.  
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ABCB1 are long acknowledged components of the cytoplasmatic membrane and KCR cells 
overexpress ABCB1 transporters resulting from DOX pressure (Kars et al., 2006). Thus, we know that 
this overexpression of ABCB1 is one of the main causes that provides them resistance to DOX. Our 
results show that after 16 weeks, KCR cells have a 9.3-fold decrease of ABCB1 mRNA expression 
(Figure 3.3). Moreover, in Western blot analysis we can observe a perceptible decrease of protein 
expression of ABCB1 (Figure 3.3). In order to assume that there was an actual decrease in the 
expression of the ABCB1 protein, we needed an internal control. We tested two probes (Na + / K + -
ATPase β1 and β-actin) and none were detected in these samples. But a Bradford was done with an R2 
= 0.9917, which indicates that probably the protein concentration was correctly quantified, and the same 
amount of protein was added to the gel. We also performed a Coomassie Brilliant Blue staining to verify 
the integrity of the proteins (Anexo D.1). The decreased expression of ABCB1 transporter was expected 
since its overexpression is maintained to overcome a selective pressure to DOX. Once this pressure 
ceases, it is expected that cells express less membrane transporters to save energy. These results have 
never been published; thus, we cannot compare the data with other publications.  
Studies performed with KCR cells and MCF-7 cells, using fluorescence microscopy and flow 
cytometry through fluorescence substrate retention assays in the presence and absence of the ABCB1 
inhibitor, VP, and DiOC2 which is a specific fluorescence substrate of this transporter, have shown that 
KCR cells have a high efflux activity of the ABCB1 transporters (Armada et al., 2019). Therefore, we did 
these assays with KCR cells in week 0, 9 and 16, to analyse if they lose activity over time. An increase 
of fluorescence was observed from week 0 to week 9 and 16, revealing that KCR cells are retaining 
more DiOC2 (Figure 3.2 and Figure 3.3). This data indicates that the cells are losing efflux activity of 
ABCB1 transporters. These results are in line with the results of western blot, and the quantification of 
ABCB1 gene by real-time qPCR. Thus, we can infer that KCR cells when cultured without DOX, lose 
the stimulus to overexpress ABCB1. Considering these results and the results of MTT assay, we showed 
that KCR cells, after 16 weeks without DOX in is cultured, are losing drug resistance.  
In the past years it has become evident that the miRNAs can play a key regulatory role in CDR 
by modulating pathways linked to drug resistance. Although most studies on the regulation of CDR by 
miRNAs focus on the dysregulation of the expression of drug transporters (Armada et al., 2019; Yang 
et al., 2013; Yano et al., 2018; Zhu et al., 2008), miRNAs can regulate drug resistance-related genes, 
alter drug targets, influence therapeutic-induced cell death, and they are involved in cell proliferation, 
cell differentiation and stress response (Dehghanzadeh et al., 2015; Drayton et al., 2014; Gomes et al., 
2016; Haenisch et al., 2013; Xu et al., 2011; Yu, 2009). Therefore, the present work had as a second 
aimed to identify miRNAs differentially expressed after loss of drug resistance, in order to associate a 
miRNA expression signature to CDR. To accomplish that, we quantified the relative expression of 1008 
miRNAs of parental KCR cells (week 0) and KCR week 16 without DOX using the control miRTC and 
the 2-ΔCT method.  
We found 23 miRNAs that were differentially expressed in the KCR cells after losing drug 
resistance, where 13 which were under expressed (hsa-miR-585-3p, hsa-miR-34a-5p, hsa-miR-877-5p, 
hsa-miR-1287-5p, hsa-miR-1182, hsa-miR-155-3p, hsa-miR-656-3p, hsa-miR-323b-5p, hsa-miR-4304, 
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hsa-miR-3691-5p, hsa-miR-676-5p, hsa-miR-4258 and hsa-miR-3177-3p), and 10 miRNAs were over 
expressed (hsa-miR-635, hsa-miR-502-5p, hsa-miR-342-3p, hsa-miR-767-5p, hsa-miR-1307-3p, hsa-
miR-1207-5p, hsa-miR-548k, hsa-miR-183-3p, hsa-miR-1193 and hsa-miR-187-5p).  
After enrichment analysis using KEGG pathways, we selected “Pathways in cancer”, 
“Proteoglycans in cancer” and “ECM-receptor interaction”, has these pathways have a bigger impact in 
drug resistance.  
For instance, examining the results in “Pathways in cancer”, 13 human miRNAs were predicted 
to target 15 genes involved in survival and apoptotic pathways. Starting with a general analysis, 9 
miRNAs (hsa-miR-1307-3p, hsa-miR-1207-5p, hsa-miR-183-3p, hsa-miR-767-5p, hsa-miR-187-5p, 
hsa-miR-635, hsa-miR-342-3p, hsa-miR-548k, hsa-miR-502-5p) of the 13 miRNAs in this pathway are 
over expressed in KCR cells sensitive to DOX. Thus, proliferative and anti-apoptotic genes (BCL-2, 
E2F3, GNAS, CTNNB1, etc.) are putatively being downregulated by these miRNAs, therefore, KCR cells 
week 16 could undergo more apoptosis and cell cycle arrest than the parental cells (Appendix, Figure 
A.2 and A.3). These results are expected, as proliferation and survival are a drug resistance phenotype 
and KCR cells lost drug resistance after 16 weeks. We did not assess apoptosis nor cell cycle arrest, 
but these assays are programmed in future studies. 
Previous studies have already reported an interaction between these miRNAs and these genes. 
For instance, Tang et al., showed that miR-1307-3p acts as a tumour suppressor inhibiting the 
expression of the BCL2 protein in colorectal carcinogenesis cell lines (Tang et al., 2015). However, Han 
et al. show that miR-1307-3p in MCF10A stimulated cell proliferation (Han et al., 2019).  
Other miRNAs from this pathway that are intriguing are the miRNAs that are under expressed 
(hsa-miR-34a-5p, hsa-miR-155-3p, hsa-miR-877-5p, hsa-miR-3691-5p). The last two never been 
reported in drug resistance, the first two have been reported as tumour suppressors and proven to 
reverse drug resistance (Gao et al., 2014; Yang et al., 2013; L. Zhang et al., 2019; Zhao et al., 2013). 
However, Pu et al., showed that miR-34a-5p is up-regulated in multi-chemoresistant cell lines compared 
to the multi-chemosensitive osteosarcoma cell lines (Pu et al., 2016) as we observe in our cells. This 
study illustrates the conflicting results on the role of the miR-34a-5p and indeed other miRNAs. A 
possible explanation for the discrepancies is that miR-34a-5p might play multi-functional roles by 
targeting different genes and might also play distinct roles in different type of cells. More studies are 
needed to elucidate the regulation mechanism of miR-34a in drug resistance.  
hsa-miR-155-3p also presents controversial results, Zhang et al. showed that miR-155-3p was 
a tumour-suppressor by targeting MYD88, affecting breast cancer cell apoptosis, migration, and 
invasion, and reversed paclitaxel resistance via negative regulation of MYD88 in MCF-7/PR cells. 
However, Zhang et al. reveal that up-regulation of miR-155-3p significantly promoted proliferation and 
repressed apoptosis of breast cancer MCF-7 cells (G. Zhang, Zhong, Luo, & Wang, 2019). This miRNA 
is also a master regulator of key processes, such as  immune response (Guruswamy & Roopa, 2019; 
Junfeng Wang et al., 2016), thus, more detailed analyses are necessary to clarify the detailed molecular 
mechanism of this regulation. 
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Notably, both the KEGG pathway and Gene Ontology analyses revealed that the most 
significantly affected putative target genes are cell cycle regulatory genes (table 4-9), such as, “cell 
cycle” “cell cycle arrest” “mitotic cell cycle” etc.  (table 9). But also, one of the “Biological process” with 
more putative gene targets are response to stress. One of the known drug resistance phenotypes 
includes overcoming drug-induced oxidative stress by enhancing their antioxidant systems (An et al., 
2017). In our study, this biological process can be regulated by 13 miRNAs, wherein 10 of them are over 
expressed (hsa-miR-635, hsa-miR-502-5p, hsa-miR-342-3p, hsa-miR-767-5p, hsa-miR-1307-3p, hsa-
miR-1207-5p, hsa-miR-548k, hsa-miR-183-3p, hsa-miR-1193, hsa-miR-187-5p). Thus, probably KCR 
cells have no longer an enhanced stress response, and KCR cells can be led more easily to induce cell 
death. 
To conclude, it is known that miRNAs can control the global activity of the cell by post-
transcriptionally regulating a large variety of target genes. Thus, they can modulate several signalling 
pathways involved in drug resistance (Dehghanzadeh et al., 2015; Drayton et al., 2014; Gomes et al., 
2016; Haenisch et al., 2013; Xu et al., 2011; Yu, 2009). Our data is in agreement with published data, 
thus, encouraging us to further investigate details of miRNA involvement in these pathways and makes 
them interesting aspirants as biomarkers in the follow-up of chemotherapy.  
 Future work is planned to ascertain the role of individual miRNA that we found differently 
expressed in drug resistance.  Moreover, we intend to use cell lines resistant to other chemotherapeutic 
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 Figure A.1: Putative target genes by the differentially expressed miRNAs in DOX-deprived KCR cells in the 


























Figure A.2. Representative examples of miRNA:gene putative interaction in KEGG category “Pathways in cancer”. A) 




































Figure B.1: Putative target genes by the differentially expressed miRNAs in DOX-deprived KCR cells in 
the KEGG category “Proteoglycans in cancer” and subcategory “Hyahuronan (HA)”. Putative target genes 
represented in orange. 
Figure B.2: Putative target genes by the differentially expressed miRNAs in DOX-deprived KCR cells in the 
KEGG category “Proteoglycans in cancer” and subcategory “Chondroitin sulfate/dermatan sulfate 




































Figure B.3: Putative target genes by the differentially expressed miRNAs in DOX-deprived KCR cells in 
the KEGG category “Proteoglycans in cancer” and subcategory Heparan sulfate proteoglycans”. 


























Figure C.1: Putative target genes by the differentially expressed miRNAs in DOX-deprived KCR cells in 
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Figure D.1: Coomassie Brilliant Blue staining of KCR cells in week 0, 10 and 15. 
